U.S. Capital Wealth Advisors’s VanEck Biotech ETF BBH Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-375	Closed	-$59.9K	–	718
2022 Q4	$59.9K	Buy	+375	New	+$59.4K	﹤0.01%	843

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

U.S. Capital Wealth Advisors's BBH Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of VanEck Biotech ETF (BBH) in Q1 2023, closing a stake of 375 shares — an estimated $59.9K sold.

U.S. Capital Wealth Advisors first reported a position in BBH in Q4 2022 and held it in 1 quarter. The position peaked at $59.9K in Q4 2022. 115 funds tracked by Wall St. Rank hold BBH as of Q1 2023.

U.S. Capital Wealth Advisors reported no remaining VanEck Biotech ETF position as of Q1 2023 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 375 VanEck Biotech ETF shares in Q1 2023, an estimated $59.9K.
U.S. Capital Wealth Advisors first reported a position in VanEck Biotech ETF in Q4 2022 and held it in 1 quarter.
U.S. Capital Wealth Advisors's VanEck Biotech ETF position peaked at $59.9K in Q4 2022.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.